Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | P4HB | P07237 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13744178 | 0.92 | CYP3A4 (0.59) | CYP3A4CYP2D6CYP2C9CYP2C19LMNA | |
| SCHEMBL2817086 | 0.86 | CYP2D6 (0.67) | CYP3A4CYP2D6CYP2C9CYP2C19LMNA | |
| SCHEMBL3510474 | 0.86 | CYP2D6 (0.55) | CYP3A4CYP2D6CYP2C9CYP2C19LMNA | |
| SCHEMBL6530831 | 0.85 | CYP2D6 (0.66) | CYP3A4CYP2D6CYP2C9CYP2C19LMNA | |
| SCHEMBL8809190 | 0.85 | CYP3A4 (0.66) | CYP3A4CYP2D6CYP2C9CYP2C19LMNA | |
| Hydrochloric Acid SCHEMBL15017981 | 0.85 | CYP2D6 (0.54) | CYP3A4CYP2D6CYP2C9CYP2C19LMNA | |
| SCHEMBL1290759 | 0.84 | CYP3A4 (0.65) | CYP3A4CYP2D6CYP2C9CYP2C19LMNA | |
| SCHEMBL11879597 | 0.83 | LMNA (0.47) | CYP3A4CYP2D6CYP2C9CYP2C19LMNA | |
| SCHEMBL7012242 | 0.83 | LMNA (0.67) | CYP3A4CYP2D6CYP2C9CYP2C19LMNA | |
| SCHEMBL16208622 | 0.83 | CYP2D6 (0.61) | CYP3A4CYP2D6CYP2C9CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014173289-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2014-10-30 | — | — | WO | disclosed |
| EP-1979319-A1 | NOVEL DUAL NK2/NK3-ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND PROCESSES FOR THEIR PREPARATIONS | Solvay Pharmaceuticals GmbH (DE) | 2008-10-15 | — | — | EP | disclosed |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| WO-2007088181-A1 | NOVEL DUAL NK2/NK3-ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND PROCESSES FOR THEIR PREPARATIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-08-09 | — | — | WO | disclosed |
| EP-1812383-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Smithkline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| EP-0739891-B1 | Substituted heterocycles | ASTRAZENECA AB (SE) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004076455-A1 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | NOVARTIS AG (CH) | 2004-09-10 | — | — | WO | disclosed |
| EP-0680962-B1 | Heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-08-20 | — | — | EP | disclosed |
| EP-0734383-B1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ASTRAZENECA AB (SE) | 2002-07-24 | — | — | EP | disclosed |
| EP-0726893-A1 | NOVEL 4-PIPERIDINYL SUBSTITUTED LACTAMES AS NEUROKININ 2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA | ZENECA LIMITED (GB) | 1996-08-21 | — | — | EP | disclosed |
| US-5534525-A | Lactam derivatives | ZENECA LIMITED (GB) | 1996-07-09 | — | — | US | disclosed |
| EP-0680962-A2 | Heterocyclic compounds | ZENECA LIMITED (GB) | 1995-11-08 | — | — | EP | disclosed |
| WO-1995016682-A1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ZENECA LIMITED (GB) | 1995-06-22 | — | — | WO | disclosed |
| WO-1995012577-A1 | NOVEL 4-PIPERIDINYL SUBSTITUTED LACTAMES AS NEUROKININ 2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA | ZENECA LIMITED (GB) | 1995-05-11 | — | — | WO | disclosed |
| US-5352788-A | Angiotensin antagonist | ELF SANOFI (FR) | 1994-10-04 | — | — | US | disclosed |
| US-5270317-A | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present | ELF SANOFI (FR) | 1993-12-14 | — | — | US | disclosed |
| EP-0121972-B1 | N-ARYL-ALPHA-AMINO-CARBOXAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-05-24 | — | — | EP | disclosed |
| EP-0121972-A2 | N-aryl-alpha-amino-carboxamides | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-10-17 | — | — | EP | disclosed |
| US-3993470-A | ISONIPECOTIC ACID DERIVATIVES, HERBICIDES | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | CYP3A4 2116/4885CYP2D6 2502/4885CYP2C9 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.